RxDoctor Payments Data

Helena Morris, APRN

Psychiatric/Mental Health · Glastonbury, CTNPI 1477010288

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.5% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,191, 6.2 times the $354 reported in 2021. Among psychiatric/mental health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,285in general payments, 2019–2025

Across 66 payments — averaging $110.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$994
  • Teva Pharmaceuticals USA, Inc.$810
  • Neurocrine Biosciences, Inc.$801
  • Alkermes, Inc.$769
  • Johnson & Johnson$724
  • AbbVie$657
  • plus $3K from 6 others

What the payments were for

  • Food & beverage$7,17498%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,285 in reported general payments places this provider in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Medicare billing

Part B allowed, 2024
$76,495
Medicare patients
105
Services billed
633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trazodone Hcl105$826
Quetiapine Fumarate51$825
Olanzapine23$329
Sertraline Hcl30$272
Escitalopram Oxalate30$271
Lorazepam16$261
Risperidone14$204
Lamotrigine15$195
Citalopram HbrCitalopram Hydrobromide11$44

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Glastonbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →